Story perspectives

GLP-1RAs Cut Major Heart Risks in Type 1 Diabetes

4/6/2026

Summary

Story summary

Initiation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 1 diabetes linked to a 15% lower risk of major adverse cardiovascular events (MACEs) and a 19% lower risk of end-stage kidney disease (ESKD).
The analysis included 174,678 type 1 diabetes patients in a national dataset.
GLP-1RA use did not increase risk of diabetic ketoacidosis or severe hypoglycemia.
The findings suggest GLP-1RAs could help prevent long-term complications in type 1 diabetes.

1 of 1

Story summary

Initiation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 1 diabetes linked to a 15% lower risk of major adverse cardiovascular events (MACEs) and a 19% lower risk of end-stage kidney disease (ESKD).
The analysis included 174,678 type 1 diabetes patients in a national dataset.
GLP-1RA use did not increase risk of diabetic ketoacidosis or severe hypoglycemia.
The findings suggest GLP-1RAs could help prevent long-term complications in type 1 diabetes.